Nivolumab In Previously Untreated Melanoma withoutBRAFMutation

·2015·DOI
Health Sciences and Innovation
Biomedical Engineering
Cancer Research and Treatment
Cancer Immunotherapy Advances

Role in the Field

Neutralin Health Sciences and Innovation
Neutralin Biomedical Engineering
Neutralin Cancer Research and Treatment
Neutralin Cancer Immunotherapy Advances

Abstract

Citations

4,846

Year

2015

PageRank

4.9 / 10

Relative influence (log-scaled)

Related Papers

10 of 10 papers

Remdesivir For The Treatment Of Covid-19 — Final Report
·2020·6,017 citations
Pembrolizumab Plus Chemotherapy In Metastatic Non–Small-Cell Lung Cancer
·2018·5,096 citations
Pembrolizumab Versus Chemotherapy For PD-L1–Positive Non–Small-Cell Lung Cancer
·2017·7,026 citations
Pembrolizumab Versus Docetaxel For Previously Treated, PD-L1-positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial.
·2016·4,714 citations
Combined Nivolumab And Ipilimumab Or Monotherapy In Untreated Melanoma
·2015·6,665 citations
Pembrolizumab For The Treatment Of Non–Small-Cell Lung Cancer
·2015·5,299 citations
Pembrolizumab Versus Ipilimumab In Advanced Melanoma
·2015·4,980 citations
PD-1 Blockade Induces Responses By Inhibiting Adaptive Immune Resistance
·2014·5,596 citations
Improved Survival With Vemurafenib In Melanoma With BRAF V600E Mutation
·2011·6,903 citations
Improved Survival With Ipilimumab In Patients With Metastatic Melanoma
·2010·13,117 citations